Investor Relations, page-11

I highly doubt that Orbimed is going to give them much of anything going forward. This group has now gotten $85 million to work with in less than 12 months and have managed to whittle that down to $18MM as of the last call. They are due another $5MM in January so you're looking at $90MM in a year's time. How much of that will be left? This of course doesn't include any receipts from customers. Although the A/R amount wasn't significant. They also didn't have pay any interest to Orbimed for a cost savings of a couple million. After 3 years of working with MedImmune where are they? Shouldn't they be supplying them with more than samples at this point? Reminds of a song where the singer says, "New verse, same as the first".